Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2

Identification of the antigens mediating response

Steven A. Rosenberg, James C. Yang, Donald E. White, Seth M. Steinberg

Research output: Contribution to journalArticle

Abstract

Objective: To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses. Methods: A consecutive series of 409 patients with either metastatic melanoma or renal cancer who were treated with high-dose bolus IL-2 in the Surgery Branch, National Cancer Institute, between September 1985 and November 1996 have been analyzed with a median potential follow-up of 7.1 years. All patients were treated with 720,000 IU/kg administered by 15-minute intravenous infusions every 8 hours for up to 5 days as clinically tolerated per cycle. Two cycles constituted a treatment course. Tumor-infiltrating lymphocytes (TIL) from melanoma patients were used to clone the genes encoding the tumor antigens responsible for clinical responsiveness. Results: Thirty-three of 409 (8.1%) patients treated with high-dose bolus IL-2 achieved a complete response and 37 (9%) achieved a partial response. Complete regression was seen in 6.6% and 9.3% of patients with metastatic melanoma and renal cancer, respectively. Twenty-seven of these 33 completely responding patients (82%) remain in ongoing continuous complete response from 39 to more than 148 months from the onset of treatment. Tumor regressions were seen at virtually all organ sites. The absence of prior treatment with immunotherapy, the total dose of IL-2 administered, and the maximal rebound lymphocytosis after cessation of IL-2 correlated with achieving a complete response. Expression cloning techniques have identified a series of tumor antigens that are recognized by TIL grown from resected melanomas. These antigens are mainly melanoma/melanocyte differentiation antigens, although mutated intracellular proteins can also serve as antigens. Conclusions: Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma. The great majority of these patients will enter durable complete regressions and appear to be cured of their metastatic cancer. Thus, immunotherapy with high- dose bolus IL-2 should be considered as initial therapy for appropriately selected patients with metastatic melanoma and renal cell cancer. Identification of the tumor antigens mediating clinical response is opening new therapeutic possibilities for cancer treatment.

Original languageEnglish (US)
Pages (from-to)307-319
Number of pages13
JournalAnnals of Surgery
Volume228
Issue number3
DOIs
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Interleukin-2
Antigens
Melanoma
Kidney Neoplasms
Neoplasms
Neoplasm Antigens
Tumor-Infiltrating Lymphocytes
Immunotherapy
Therapeutics
Melanoma-Specific Antigens
Lymphocytosis
National Cancer Institute (U.S.)
Melanocytes
Differentiation Antigens
Renal Cell Carcinoma
Intravenous Infusions
Organism Cloning
Clone Cells
Genes

ASJC Scopus subject areas

  • Surgery

Cite this

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2 : Identification of the antigens mediating response. / Rosenberg, Steven A.; Yang, James C.; White, Donald E.; Steinberg, Seth M.

In: Annals of Surgery, Vol. 228, No. 3, 09.1998, p. 307-319.

Research output: Contribution to journalArticle

Rosenberg, Steven A. ; Yang, James C. ; White, Donald E. ; Steinberg, Seth M. / Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2 : Identification of the antigens mediating response. In: Annals of Surgery. 1998 ; Vol. 228, No. 3. pp. 307-319.
@article{7a7a4e0db235441da1c1d523e1d33d1c,
title = "Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response",
abstract = "Objective: To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses. Methods: A consecutive series of 409 patients with either metastatic melanoma or renal cancer who were treated with high-dose bolus IL-2 in the Surgery Branch, National Cancer Institute, between September 1985 and November 1996 have been analyzed with a median potential follow-up of 7.1 years. All patients were treated with 720,000 IU/kg administered by 15-minute intravenous infusions every 8 hours for up to 5 days as clinically tolerated per cycle. Two cycles constituted a treatment course. Tumor-infiltrating lymphocytes (TIL) from melanoma patients were used to clone the genes encoding the tumor antigens responsible for clinical responsiveness. Results: Thirty-three of 409 (8.1{\%}) patients treated with high-dose bolus IL-2 achieved a complete response and 37 (9{\%}) achieved a partial response. Complete regression was seen in 6.6{\%} and 9.3{\%} of patients with metastatic melanoma and renal cancer, respectively. Twenty-seven of these 33 completely responding patients (82{\%}) remain in ongoing continuous complete response from 39 to more than 148 months from the onset of treatment. Tumor regressions were seen at virtually all organ sites. The absence of prior treatment with immunotherapy, the total dose of IL-2 administered, and the maximal rebound lymphocytosis after cessation of IL-2 correlated with achieving a complete response. Expression cloning techniques have identified a series of tumor antigens that are recognized by TIL grown from resected melanomas. These antigens are mainly melanoma/melanocyte differentiation antigens, although mutated intracellular proteins can also serve as antigens. Conclusions: Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8{\%} of patients with metastatic renal cancer and melanoma. The great majority of these patients will enter durable complete regressions and appear to be cured of their metastatic cancer. Thus, immunotherapy with high- dose bolus IL-2 should be considered as initial therapy for appropriately selected patients with metastatic melanoma and renal cell cancer. Identification of the tumor antigens mediating clinical response is opening new therapeutic possibilities for cancer treatment.",
author = "Rosenberg, {Steven A.} and Yang, {James C.} and White, {Donald E.} and Steinberg, {Seth M.}",
year = "1998",
month = "9",
doi = "10.1097/00000658-199809000-00004",
language = "English (US)",
volume = "228",
pages = "307--319",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2

T2 - Identification of the antigens mediating response

AU - Rosenberg, Steven A.

AU - Yang, James C.

AU - White, Donald E.

AU - Steinberg, Seth M.

PY - 1998/9

Y1 - 1998/9

N2 - Objective: To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses. Methods: A consecutive series of 409 patients with either metastatic melanoma or renal cancer who were treated with high-dose bolus IL-2 in the Surgery Branch, National Cancer Institute, between September 1985 and November 1996 have been analyzed with a median potential follow-up of 7.1 years. All patients were treated with 720,000 IU/kg administered by 15-minute intravenous infusions every 8 hours for up to 5 days as clinically tolerated per cycle. Two cycles constituted a treatment course. Tumor-infiltrating lymphocytes (TIL) from melanoma patients were used to clone the genes encoding the tumor antigens responsible for clinical responsiveness. Results: Thirty-three of 409 (8.1%) patients treated with high-dose bolus IL-2 achieved a complete response and 37 (9%) achieved a partial response. Complete regression was seen in 6.6% and 9.3% of patients with metastatic melanoma and renal cancer, respectively. Twenty-seven of these 33 completely responding patients (82%) remain in ongoing continuous complete response from 39 to more than 148 months from the onset of treatment. Tumor regressions were seen at virtually all organ sites. The absence of prior treatment with immunotherapy, the total dose of IL-2 administered, and the maximal rebound lymphocytosis after cessation of IL-2 correlated with achieving a complete response. Expression cloning techniques have identified a series of tumor antigens that are recognized by TIL grown from resected melanomas. These antigens are mainly melanoma/melanocyte differentiation antigens, although mutated intracellular proteins can also serve as antigens. Conclusions: Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma. The great majority of these patients will enter durable complete regressions and appear to be cured of their metastatic cancer. Thus, immunotherapy with high- dose bolus IL-2 should be considered as initial therapy for appropriately selected patients with metastatic melanoma and renal cell cancer. Identification of the tumor antigens mediating clinical response is opening new therapeutic possibilities for cancer treatment.

AB - Objective: To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses. Methods: A consecutive series of 409 patients with either metastatic melanoma or renal cancer who were treated with high-dose bolus IL-2 in the Surgery Branch, National Cancer Institute, between September 1985 and November 1996 have been analyzed with a median potential follow-up of 7.1 years. All patients were treated with 720,000 IU/kg administered by 15-minute intravenous infusions every 8 hours for up to 5 days as clinically tolerated per cycle. Two cycles constituted a treatment course. Tumor-infiltrating lymphocytes (TIL) from melanoma patients were used to clone the genes encoding the tumor antigens responsible for clinical responsiveness. Results: Thirty-three of 409 (8.1%) patients treated with high-dose bolus IL-2 achieved a complete response and 37 (9%) achieved a partial response. Complete regression was seen in 6.6% and 9.3% of patients with metastatic melanoma and renal cancer, respectively. Twenty-seven of these 33 completely responding patients (82%) remain in ongoing continuous complete response from 39 to more than 148 months from the onset of treatment. Tumor regressions were seen at virtually all organ sites. The absence of prior treatment with immunotherapy, the total dose of IL-2 administered, and the maximal rebound lymphocytosis after cessation of IL-2 correlated with achieving a complete response. Expression cloning techniques have identified a series of tumor antigens that are recognized by TIL grown from resected melanomas. These antigens are mainly melanoma/melanocyte differentiation antigens, although mutated intracellular proteins can also serve as antigens. Conclusions: Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma. The great majority of these patients will enter durable complete regressions and appear to be cured of their metastatic cancer. Thus, immunotherapy with high- dose bolus IL-2 should be considered as initial therapy for appropriately selected patients with metastatic melanoma and renal cell cancer. Identification of the tumor antigens mediating clinical response is opening new therapeutic possibilities for cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=0032471712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032471712&partnerID=8YFLogxK

U2 - 10.1097/00000658-199809000-00004

DO - 10.1097/00000658-199809000-00004

M3 - Article

VL - 228

SP - 307

EP - 319

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -